Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPOCH II vs EPOCH II + Immunotherapy in Lymphomas
NCT00001430Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 1995
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aldesleukin in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by National Cancer Institute. Started Feb 1995; status: completed.
02
Drugs
aldesleukin
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00001430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001430.